Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Our volunteers generously give us their time, skills and experience to tell people about our work, and to help us raise vital funds for research into better treatments and ultimately a cure for T1D.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Your donation helps support people living with type 1 diabetes and funds the best treatment and cure research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > Team of international scientific experts to advise on £50 million investment into type 1 diabetes research
The Type 1 Diabetes Grand Challenge – a partnership between the Steve Morgan Foundation, Diabetes UK and JDRF UK– has successfully appointed 17 leading international scientists to advise on its £50 million investment into type 1 diabetes research.
The scientists have joined one of three independent Scientific Advisory Panels each advising on a research area identified as having the greatest potential to transform treatments for type 1 diabetes:
All three Panels are Chaired by Professor Simon Heller, a world-renowned diabetes specialist.
Further information on the Grand Challenge’s scope and ambition, and membership of the Scientific Advisory Panels, can be found on the Partnership’s new website.
The site also features latest Grand Challenge news, information about funding opportunities and funded projects. When research projects are underway it will also demonstrate and celebrate their impact.
Rachel Connor, Director of Research Partnerships at JDRF UK said: “We’re delighted to welcome so many globally renowned scientists, who are already giving us the benefit of their insight and expertise as we shape this Grand Challenge. They are ensuring the research we support through this game-changing partnership will best meet the needs of people living with type 1. The calibre of membership we’ve been able to attract to the new panels is testament to how thrilling the new research, supported by the partnership, will be.”
Dr Elizabeth Robertson, Director of Research at Diabetes UK said: “We are honoured to have so many of the world’s most distinguished diabetes researchers advising the Type 1 Diabetes Grand Challenge. Their expertise will help to ensure that every penny of the Steve Morgan Foundation’s £50 million gift is invested in bold, innovative research with the greatest potential to improve the lives of people with type 1 diabetes.
“We’re delighted to see the global research community united in their support of the Type 1 Diabetes Grand Challenge and look forward to seeing new, exciting research focusing on accelerating progress towards a cure for type 1 diabetes get underway next year.”
The new website can be found at type1diabetesgrandchallenge.org.uk
Researchers funded by Breakthrough T1D in America have used small, electrical implant systems in lab-grown, insulin-producing cells.
New research suggests that B cells play a major role in damaging protective immune cells called Tregs. Protecting Tregs could help protect insulin-producing cells in the early stages of T1D.
A major UK study has shown that screening children for type 1 diabetes (T1D) can identify the condition in its earliest stages, before symptoms appear, offering families time, choices, and hope.
The European Commission has approved Teizeild, the European brand name for the immunotherapy teplizumab, for use in people with stage 2 type 1 diabetes (T1D). This marks an important step forward in efforts to delay the progression of the condition.
Don’t miss out on the latest research, inspiring stories, tech news, upcoming events, and handy information on living well with type 1. Join us now and receive it all straight to your inbox.
It’s thanks to your dedication that we have funded great progress in type 1 cure, treatment and prevention research. Help us to continue our vital research.
